We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis

By LabMedica International staff writers
Posted on 17 May 2024

Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. More...

Traditional intraoperative assessments, such as frozen sections based on H&E histology, are demanding in terms of time, resources, and labor and also raise concerns about specimen consumption. D-FFOCT, a high-resolution optical imaging technology, allows for the quick generation of virtual histology. Researchers have now developed an intraoperative diagnostic workflow that uses deep learning algorithms to classify tumors from D-FFOCT images, offering rapid and automated diagnosis for surgical decision-making.

A prospective cohort study conducted by researchers from Peking University People’s Hospital (Beijing, China) included 224 breast samples imaged using D-FFOCT. This imaging technique is non-destructive and requires no tissue preparation or staining. The D-FFOCT images were segmented into patches, and slides were allocated into a training set (182 slides, 10,357 patches) and an external testing set (42 slides, 3,140 patches) based on the order in which they were collected. A five-fold cross-validation method was employed to train and fine-tune the model. A machine learning model aggregated the patch prediction results to the slide level after feature extraction.

The testing set showed the model performed well at the patch level, identifying breast tissue types with an AUC of 0.926 (95% CI: 0.907–0.943). At the slide level, the diagnostic accuracy reached 97.62%, with a sensitivity of 96.88% and a specificity of 100%. Accuracy did not significantly differ across various molecular subtypes and histologic tumor types of breast cancer. Visualization heatmaps demonstrated that the deep learning models could identify features corresponding to metabolically active cell clusters in D-FFOCT images, aligning with expert assessments. This image analysis approach could potentially extend to various tumor types, given the conserved features detected in the model. In a margin simulation experiment, the diagnosis process took about three minutes, with the deep learning model achieving a high accuracy of 95.24%.

Based on the results, the study has proposed an intraoperative cancer diagnosis workflow integrating D-FFOCT with a deep learning model. In simulated intraoperative margin diagnosis, the workflow substantially reduced diagnosis time by about tenfold compared to traditional methods and proved to be highly cost-effective in terms of labor. No tissue was destroyed during optical imaging and analysis. Overall, this workflow offers a transparent solution for rapid and accurate intraoperative diagnosis, potentially guiding surgical decisions effectively.

Related Links:
Peking University People’s Hospital 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.